Evidence map›Paper›PMID 32859169›Full record

ArticleBMC cancer2020

Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome.

Luciana Yamamoto de Almeida, Diego Antonio Pereira-Martins, Ana Sílvia Gouvêa Lima, Márcia Sueli Baggio, Luisa Corrêa de Araujo Koury, Ana Paula Lange, Sarah Cristina Bassi, Priscila Santos Scheucher, Eduardo Magalhães Rego

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Luciana Yamamoto de AlmeidaHematology Division, Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil.
Diego Antonio Pereira-MartinsHematology Division, Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil.
Ana Sílvia Gouvêa LimaHematology Division, Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil.
Márcia Sueli BaggioHemostasis Laboratory, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, University of Sao Paulo, Ribeirao Preto, Brazil.
Luisa Corrêa de Araujo KouryHematology Division, Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil.
Ana Paula LangeHematology Division, Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil.
Sarah Cristina BassiCenter for Cell Based Therapy, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil.
Priscila Santos ScheucherHematology Division, Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil.
Eduardo Magalhães RegoHematology Division, Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil. eduardo.rego@fm.usp.br.ORCID http://orcid.org/0000-0003-1567-4086
Universidade de São Paulo · BR

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2013/08135-2Fundação de Amparo à Pesquisa do Estado de São Paulo 2016/02713-2Fundação de Amparo à Pesquisa do Estado de São Paulo 2017/23117-1
6 · The paper itself

Abstract

backgroundDifferentiation syndrome (DS) is the main life-threatening adverse event that occurs in acute promyelocytic leukemia (APL) patients treated with all-trans retinoic acid (ATRA). Cytokine imbalances have been reported to play role during the developing of acute promyelocytic leukemia differentiation syndrome (APL-DS). However, the relationship between the plasma cytokine levels and their prognostic value for the prediction of DS developing in patients with APL during the treatment with ATRA and anthracyclines has not been previously reported.

methodsIn this study, we followed an APL cohort (n = 17) over 7 days of ATRA therapy in DS (n = 6) and non-DS groups (n = 11). Interleukin (IL)-1β, IL-6, IL-8, IL-10, IL-12p70 and TNF-α were measured in the peripheral blood plasma from 17 patients with APL and 11 healthy adult controls by using the cytometric bead array method.

resultsIn non-DS patients, IL-8 plasma levels were significantly reduced in the seventh day of ATRA treatment (34.16; 6.99 to 147.11 pg mL

conclusionsWe demonstrated that the modulation of IL-8 following ATRA treatment may occur regardless of the development of DS and, therefore, does not appear to be a predictive biomarker to monitor the APL-DS.

Indexed as

AdultAgedAntineoplastic AgentsBiomarkers, TumorCell DifferentiationFemaleHumansInterleukin-6Interleukin-8Leukemia, Promyelocytic, AcuteMaleMiddle AgedRetrospective StudiesSyndromeTreatment OutcomeTretinoinAntineoplastic AgentsBiomarkers, TumorCXCL8 protein, humanIL6 protein, humanInterleukin-6Interleukin-8TretinoinAcute promyelocytic leukemiaDifferentiation syndromeInterleukin-6 (IL-6)Interleukin-8 (IL-8)

Identifiers

PMID32859169
PMCPMC7456372
OpenAlexW3082353336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.